CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 73 enrolled
Drug / intervention
Triamcinolone Acetonidedrug
Likely dose
Triamcinolone Acetonide 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05413330
NCT05413330Phase 3Completed
CompareCT.gov

Combined Phacoemulsification Surgery and Intravitreal Triamcinolone Injection Versus Stand-alone Surgery in Patients With Type 2 Diabetes: A Randomized Controlled Trial

Damascus University·interventional·Posted Jun 10, 2022·Updated Apr 26, 2023

In Brief

A Phase 3 clinical trial evaluating Triamcinolone Acetonide for Diabete Type 2 and 3 related conditions. Completed, enrolled 73 participants across 1 site.

Detailed Summary

The investigators aim in this study to investigate the effect of intravitreal triamcinolone acetonide injection on the development of macular edema and the progression of diabetic retinopathy. Whether this injection hastens cataract surgery results or not. The investigators will categorize the participants into two groups: the case group who will receive the injection at the end of the surgery, and the control group who will have routine cataract surgery with no extra injections.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabete Type 2, Cataract, Triamcinolone Acetonide, Intravitreal Injection
CountriesSyria
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedJun 10, 2022
Enrollment StartSep 12, 2020
Primary CompletionJan 5, 2022
Study CompletionMar 29, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.1 years ago

Interventions

Triamcinolone Acetonidedrug

Intravitreal injection of 4 mg/0.1 mL preservative-free triamcinolone acetonide at the end of phacoemulsification surgery will be injected at 3.5 mm inferolateral and posterior to the limbus.